Tolerability and beneficial effects of sacubitril/valsartan on systemic right ventricular failure.
Marieke NederendPhilippine KièsMadelien V RegeerHubert W VliegenBart Ja MertensDaniëlle Robbers-VisserBerto Jorrit BoumaLaurens F TopsMartin J SchalijMonique R M JongbloedAnastasia D EgorovaPublished in: Heart (British Cardiac Society) (2023)
Treatment with sacubitril/valsartan was associated with a low rate of adverse effects in this adult sRV cohort. Persisting improvement in 6-minute walking test distance, NT-proBNP levels and echocardiographic parameters of sRV function was observed in an on-treatment analysis and showed no differential response based on sex or anatomy.